APP and Alzheimer disease: The significant adverse effects described in clinical studies [53, 54] have revealed the gaps and urgent needs in understanding the molecular and cellular pathways that regulate the activity of γ-secretase, APP processing and Aβ production in early- and late-onset AD in order to design safe and potent drugs against AD.